Marathon Pharmaceuticals LLC has struck a deal to sell its muscular dystrophy treatment to PTC Therapeutics Inc., one month after Marathon’s $89,000 price-tag for the drug spurred an outcry from patient advocates and federal lawmakers. Marathon will receive $140 million up front from the sale—$75 million in cash and about $65 million in PTC stock. It will also be entitled to certain payments based on sales of the drug starting in...

Source: Wall Street Journal March 16, 2017 13:16 UTC